Globus Medical, Inc. $GMED Shares Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its position in shares of Globus Medical, Inc. (NYSE:GMED) by 10.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 718,060 shares of the medical device company’s stock after buying an additional 69,486 shares during the period. Stephens Investment Management Group LLC’s holdings in Globus Medical were worth $41,123,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GMED. Boston Trust Walden Corp acquired a new position in Globus Medical during the 3rd quarter worth approximately $67,891,000. Norges Bank purchased a new stake in shares of Globus Medical during the second quarter valued at approximately $68,038,000. Marshall Wace LLP lifted its position in shares of Globus Medical by 89.7% during the second quarter. Marshall Wace LLP now owns 1,580,476 shares of the medical device company’s stock worth $93,280,000 after purchasing an additional 747,330 shares in the last quarter. Burgundy Asset Management Ltd. boosted its stake in shares of Globus Medical by 24.3% in the second quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after purchasing an additional 679,691 shares during the period. Finally, Sculptor Capital LP grew its holdings in Globus Medical by 31.9% during the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Trading Down 0.3%

GMED stock opened at $93.60 on Friday. The stock’s 50 day simple moving average is $88.43 and its 200 day simple moving average is $69.06. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market cap of $12.53 billion, a P/E ratio of 30.19, a P/E/G ratio of 1.57 and a beta of 1.06.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.39. The firm had revenue of $769.05 million during the quarter, compared to analyst estimates of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.83 earnings per share. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Barclays upped their price objective on shares of Globus Medical from $106.00 to $114.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Weiss Ratings restated a “hold (c)” rating on shares of Globus Medical in a research note on Wednesday, October 8th. Stifel Nicolaus started coverage on Globus Medical in a research report on Tuesday, October 28th. They issued a “hold” rating and a $64.00 target price on the stock. Citigroup reissued a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Finally, Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Eight investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.78.

Insider Activity at Globus Medical

In related news, Director Ann D. Rhoads sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $81.00, for a total transaction of $648,000.00. Following the completion of the transaction, the director owned 17,384 shares in the company, valued at $1,408,104. The trade was a 31.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kyle Kline sold 18,542 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $90.00, for a total value of $1,668,780.00. The SEC filing for this sale provides additional information. In the last three months, insiders sold 91,636 shares of company stock valued at $7,984,583. 18.51% of the stock is owned by insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.